Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research describing ASDAS LDA achievement among patients treated with biologic DMARDs (bDMARD) is limited. The aim of this study was to describe disease activity and patient-reported outcome measures (PROMs) among patients […]

The electronic medical record management systems may improve

PDF) Golimumab as the First-, Second-, or at Least Third-Line

Dual neutralisation of interleukin-17A and interleukin-17F with

Real-world effectiveness of golimumab in adult patients with

Impact of tapering targeted therapies (bDMARDs or JAKis) on the

PDF) Work Disability in Axial Spondyloarthritis

The state of the art—psoriatic arthritis outcome assessment in

Relationship between disease activity status or clinical response

Performance of 3 Composite Measures for Disease Activity in

Frontiers Targeted Therapies in Axial Psoriatic Arthritis

ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response

Full article: Effectiveness of bDMARDs in ankylosing spondylitis